Shamburg News · 8-K filed Nov 10, 2026, 8:03 AM EST
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
TYRA · Tyra Biosciences, Inc.
- Earnings
- Materiality: high
Tyra Biosciences, Inc. reported financial results for the quarter ended September 30, 2026, with a net loss of $51.1 million compared to $29.9 million a year earlier. Research and development expenses were $43.1 million and general and administrative expenses were $11.7 million for the quarter. The company reported cash, cash equivalents and marketable securities of $700.5 million as of September 30, 2026, and said it expects to fund planned operations through 2030 following a September 2026 financing of approximately $400 million in gross proceeds.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-454474.
Written from the filing by Shamburg Markets. Figures are as reported by the company.